{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T20:27:05Z","timestamp":1774556825769,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.farma.2025.05.008","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T03:16:54Z","timestamp":1751426214000},"page":"47-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy in advanced endometrial cancer with microsatellite instability: A systematic review"],"prefix":"10.1016","volume":"50","author":[{"given":"Cristina","family":"Moreno-Ramos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel David","family":"Gil-Sierra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda del Pilar","family":"Brice\u00f1o-Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.farma.2025.05.008_bb0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.farma.2025.05.008_bb0010","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.farma.2025.05.008_bb0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12935-019-1091-8","article-title":"Microsatellite instability: a review of what the oncologist should know","volume":"20","author":"Li","year":"2020","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.farma.2025.05.008_bb0020","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ijc.31300","article-title":"Three molecular pathways model colorectal carcinogenesis in Lynch syndrome","volume":"143","author":"Ahadova","year":"2018","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.farma.2025.05.008_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003777","volume":"10","author":"Oaknin","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"20","key":"10.1016\/j.farma.2025.05.008_bb0030","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1200\/JCO.2009.27.0652","article-title":"Clinical relevance of microsatellite instability in colorectal cancer","volume":"28","author":"De la Chapelle","year":"2010","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.farma.2025.05.008_bb0035","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.1158\/0008-5472.CAN-09-0358","article-title":"Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases","volume":"69","author":"Mueller","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.farma.2025.05.008_bb0040","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN Guidelines). Uterine neoplasms. Version 2.2024; 2024 [accessed 6 June 2024]. Available in: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/uterine.pdf."},{"issue":"9","key":"10.1016\/j.farma.2025.05.008_bb0045","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaoncol.2015.2151","article-title":"Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1","volume":"1","author":"Howitt","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.farma.2025.05.008_bb0050","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews","volume":"14","author":"Methley","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.farma.2025.05.008_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.farma.2025.05.008_bb0060","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (Version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.farma.2025.05.008_bb0065","unstructured":"Cochrane methods bias. Risk Of Bias In Non-randomized Studies of Interventions, Version 2 (ROBINS-I V2); 2025 [accessed 5 March 2025]. Available in: https:\/\/methods.cochrane.org\/bias\/risk-bias-nonrandomized-studies-interventions."},{"issue":"7","key":"10.1016\/j.farma.2025.05.008_bb0070","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study","volume":"40","author":"O'Malley","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.farma.2025.05.008_bb0075","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/cncr.34025","article-title":"A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability","volume":"128","author":"Bellone","year":"2022","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.farma.2025.05.008_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.farma.2025.05.008_bb0085","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.farma.2025.05.008_bb0090","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Makker","year":"2019","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.farma.2025.05.008_bb0095","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.farma.2025.05.008_bb0100","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.farma.2025.05.008_bb0105","unstructured":"Spanish Agency for Medicines and Health Products. Technical label of durvalumab (Imfinzi\u00ae); 2023 [accessed 15 May 2023]. Available in: https:\/\/cima.aemps.es\/cima\/pdfs\/ft\/1181322001\/FT_1181322001.pdf."},{"issue":"6","key":"10.1016\/j.farma.2025.05.008_bb0110","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002255","article-title":"Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer: a nonrandomized phase 2 clinical trial","volume":"9","author":"Antill","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.farma.2025.05.008_bb0115","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ygyno.2022.11.028","article-title":"Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: a randomized open-label phase 2 study","volume":"169","author":"Rubinstein","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.farma.2025.05.008_bb0120","unstructured":"Spanish Agency for Medicines and Health Products. Technical label of dostarlimab (Jemperli\u00ae); 2023 [accessed 20 May 2023]. Available in: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1211538001\/FT_1211538001.html."},{"issue":"11","key":"10.1016\/j.farma.2025.05.008_bb0125","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/jamaoncol.2020.4515","article-title":"Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial","volume":"6","author":"Oaknin","year":"2020","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.farma.2025.05.008_bb0130","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial","volume":"6","author":"Andr\u00e9","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.farma.2025.05.008_bb0135","unstructured":"Spanish Agency for Medicines and Health Products. Technical label of nivolumab (Opdivo\u00ae); 2020 [accessed 20 May 2023]. Available in: https:\/\/cima.aemps.es\/cima\/pdfs\/ft\/1151014001\/FT_1151014001.pdf."},{"issue":"3","key":"10.1016\/j.farma.2025.05.008_bb0140","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.19.00818","article-title":"Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: results from arm Z1D-A subprotocol of the NCI-MATCH (EAY131) study","volume":"38","author":"Azad","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.farma.2025.05.008_bb0145","unstructured":"Spanish Agency for Medicines and Health Products. Technical label of avelumab (Bavencio\u00ae); 2020 [accessed 20 May 2023]. Available in: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1171214001\/FT_1171214001.html."},{"issue":"30","key":"10.1016\/j.farma.2025.05.008_bb0150","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1200\/JCO.19.01021","article-title":"Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent\/persistent endometrial cancer","volume":"37","author":"Konstantinopoulos","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.farma.2025.05.008_bb0155","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/1078-0432.CCR-15-1678","article-title":"Microsatellite instability as a biomarker for PD-1 blockade","volume":"22","author":"Dudley","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.farma.2025.05.008_bb0160","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) summary of opinion (initial authorisation) for dostarlimab (Jemperli\u00ae); 2021 [accessed 5 June 2023]. Available in: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-jemperli_en.pdf."},{"key":"10.1016\/j.farma.2025.05.008_bb0165","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) summary of opinion (post authorisation) for pembrolizumab (Keytruda\u00ae); 2022 [accessed 5 June 2023]. Available in: https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-109-ii-117_en.pdf."},{"issue":"23","key":"10.1016\/j.farma.2025.05.008_bb0170","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.farma.2025.05.008_bb0175","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial dancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.farma.2025.05.008_bb0180","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/jcpt.13102","article-title":"Checklist for clinical applicability of subgroup analysis","volume":"45","author":"Gil-Sierra","year":"2020","journal-title":"J Clin Pharm Ther"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S113063432500073X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S113063432500073X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T02:24:33Z","timestamp":1767579873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S113063432500073X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S113063432500073X"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2025.05.008","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy in advanced endometrial cancer with microsatellite instability: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2025.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H).","name":"copyright","label":"Copyright"}]}}